Bank of Montreal
PLX icon

Bank of Montreal’s Protalix BioTherapeutics PLX Stock Holding History

Bank of Montreal’s Portfolio PLX Stock Details PLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-161,220
Closed -$605K – 5072
2020
Q3 		$605K Sell
161,220
-12,484
-7% -$45.1K ﹤0.01% 2239
2020
Q2 		$615K Buy
+173,704
New +$594K ﹤0.01% 2162

Other funds holding PLX

BCM
Burrage Capital Management Boston, Massachusetts $99.7M AUM 66.05% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
PVH
Psagot Value Holdings Tel Aviv, Israel $11M AUM 32.09% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Bank of Montreal's PLX Position: Q4 2020 in Review

Bank of Montreal sold out of Protalix BioTherapeutics (PLX) in Q4 2020, closing a stake of 161,220 shares — an estimated $605K sold.

Bank of Montreal first reported a position in PLX in Q2 2020 and held it in 2 quarters. The position peaked at $615K in Q2 2020. 23 funds tracked by Wall St. Rank hold PLX as of Q4 2020.

  • Bank of Montreal reported no remaining Protalix BioTherapeutics position as of Q4 2020 after selling out during the quarter.
  • Bank of Montreal sold 161,220 Protalix BioTherapeutics shares in Q4 2020, an estimated $605K.
  • Bank of Montreal first reported a position in Protalix BioTherapeutics in Q2 2020 and held it in 2 quarters.
  • Bank of Montreal's Protalix BioTherapeutics position peaked at $615K in Q2 2020.
  • 23 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q4 2020.

Based on Bank of Montreal's 13F filing for Q4 2020, filed 12 Feb 2021.